Bioforge Hivegen, often known as BioGen, is a multiplanetary genetic engineering conglomerate headquartered in Lausanne, Switzerland. It is best known for its synth specialised in personalised medicine and agricultural optimisation, as well as its organic electronic and cosmetic products. It has divisions producing products in many parts of the bio-economy including mRNA therapies where it competes with Pharmatica Group, but its largest revenue streams are from CRISPR editing applications such as crop improvement, organ transplants, and tailored synthetic organisms. It also a is the leading provider of personalised medicine therapies, with its partial cellular reprogramming product positioned as a more expensive alternative to Pharmatica's senolytic Renovacel.

Hivegen originated as a commercial spin off from an Australian Collaborative Research Center in food quality optimization, with early products such as honey quality optimization and bio-fortified bananas. They achieved early success licensing their natural flavor engineering product lines, which used bio-engineered proteins to rebalance the flavours of several popular foods, to food retailers. Hivegen's use of gene editing to produce more resilient bees with enhanced pollination capabilities is likely to have saved bees from extinction, and resulted in a Russ and Tyler Prize for two of their scientists. Hivegen developed the original engineered RuBisCO proteins which eventually helped kickstart the fourth agricultural revolution after their acquisition by Bioforge. Hivegen is also notable for being the majority funder of the successful woolly mammoth de-extinction project as a promotional initiative for their exotic lab grown meat and animal product lines.

Bioforge was a German phytomining joint venture between BASF and Bayer CropScience that achieved success as a low cost method of extracting rare earth elements from otherwise marginal mining land. As they were developing a large amount of valuable IP outside the core competencies of either company, such as many novel hyperaccumulator plant strains, and were starting to move into legally risky areas such as synthetic organisms and mRNA production platforms, an independent company was eventually created. The company was very successful in developing plant strains suited for the vast ex-petrostate solar desalinisation desert farms. Their success allowed them to control much of the Eurasian Bloc bio-regulation, which helped them to acquire Hivegen in 61 BFC while it was fighting several battles with regulatory agencies over breeding extinct animals on stations outside of the jurisdiction of animal welfare treaties.